Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Biogen Idec shares are up 60% since I profiled the company in Forbes in December. The reason’s pretty simple: sales of the MS drug Tecfidera are basically destroying what were already very high expectations. Mark Schoenebaum at International Strategy & Investment Group noted on Tuesday that according to data from IMS Health, prescriptions for Tecfidera went up 21% last week. Even if patients start dropping off the drug at a 10% rate and weekly additions slow, sales could still hit $800 million this year, about double what analysts had expected before the launch. This graph is Schoenebaum’s, and it compares Tecfidera’s launch to those of Novartis ‘ Gilenya and Sanofi ‘s Aubagio, the other new MS pills.
Help employers find you! Check out all the jobs and post your resume.
Biogen Idec shares are up 60% since I profiled the company in Forbes in December. The reason’s pretty simple: sales of the MS drug Tecfidera are basically destroying what were already very high expectations. Mark Schoenebaum at International Strategy & Investment Group noted on Tuesday that according to data from IMS Health, prescriptions for Tecfidera went up 21% last week. Even if patients start dropping off the drug at a 10% rate and weekly additions slow, sales could still hit $800 million this year, about double what analysts had expected before the launch. This graph is Schoenebaum’s, and it compares Tecfidera’s launch to those of Novartis ‘ Gilenya and Sanofi ‘s Aubagio, the other new MS pills.
Help employers find you! Check out all the jobs and post your resume.
